Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04164082 |
Recruitment Status :
Recruiting
First Posted : November 15, 2019
Last Update Posted : February 24, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bladder Urothelial Carcinoma In Situ Infiltrating Bladder Mixed Carcinoma Stage 0a Bladder Cancer AJCC v8 Stage 0is Bladder Cancer AJCC v8 Stage I Bladder Cancer AJCC v8 | Drug: Gemcitabine Hydrochloride Biological: Pembrolizumab | Phase 2 |


PRIMARY OBJECTIVES:
I. Estimate the 6-month complete response rate of treatment with intravesical gemcitabine hydrochloride (gemcitabine) in combination with MK-3475 (pembrolizumab) in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) that have a carcinoma in situ (CIS) component.
II. Estimate the 18 month event-free survival (EFS) rate for all patients with BCG-unresponsive NMIBC receiving intravesical gemcitabine in combination with MK-3475 (pembrolizumab).
SECONDARY OBJECTIVES:
I. To characterize the safety profile of the combination of intravesical gemcitabine with MK-3475 (pembrolizumab) with BCG-unresponsive NMIBC (CIS or high grade Ta and T1 with or without a CIS component).
II. To estimate progression-free survival (PFS) of patients with BCG-unresponsive NMIBC treated with intravesical gemcitabine in combination with MK-3475 (pembrolizumab).
III. To estimate overall survival (OS) of patients with BCG-unresponsive NMIBC treated with intravesical gemcitabine in combination with MK-3475 (pembrolizumab).
IV. To estimate cystectomy-free survival of patients with BCG-unresponsive NMIBC treated with intravesical gemcitabine in combination with MK-3475 (pembrolizumab).
V. To estimate recurrence-free survival (RFS) for patients with a CIS component only and those without a CIS component.
EXPLORATORY OBJECTIVES:
I. To assess correlation between tumor mutation burden (TMB) and EFS and 6-month complete response (CR) rate.
II. To assess correlation between specific genomic alterations (single nucleotide variant [SNV] and copy number gains/loss) and EFS and 6-month complete response rate.
III. To assess correlation between APOBEC mutational signature and EFS and 6-month complete response rate.
IV. To assess correlation between immune gene signatures (IGS) and EFS and 6-month complete response rate.
V. To assess correlation between PD-L1 ribonucleic acid (RNA) levels and EFS and 6-month complete response rate.
VI. To assess correlation between RNA molecular subtype and EFS and 6-month complete response rate.
VII. To assess correlation between intratumoral T-cell receptor (TCR) clonality and EFS and 6-month complete response rate.
VIII. To assess correlation between changes in peripheral blood TCR clonality and EFS and 6-month complete response rate.
IX. To assess EFS in patients with urine cell free deoxyribonucleic acid (DNA) (cfDNA) + versus (vs.) patients with cfDNA.
OUTLINE:
INDUCTION: Patients receive pembrolizumab intravenously (IV) over 25-40 minutes on day 1 of cycles 1-4. Patients also receive gemcitabine hydrochloride intravesically on days 1, 8 and 15 of cycles 1 and 2. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Beginning cycle 5, patients with no evidence of disease after induction receive pembrolizumab IV over 25-40 minutes and gemcitabine intravesically on day 1. Treatment repeats every 3 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients with evidence of disease (recurrence or progression) or stop study treatment to receive non-protocol treatment during induction are followed up every 6 months for 5 years. Patients who go off treatment due to any reason other than recurrence/progression or receiving subsequent non-protocol treatment during induction will go to clinical follow-up until evidence of disease progression/recurrence. Thereafter, patients are followed up every 6 months until 5 years from registration. Patients who complete scheduled maintenance treatment according to protocol therapy are followed up every 3 months for 2 years and then every 6 months for 3 years until disease progression/recurrence or receiving subsequent non-protocol treatment. Thereafter, patients are followed up every 6 months until 5 years from registration. Patients who have evidence of disease during maintenance therapy are followed up every 6 months until 5 years from registration.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 161 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer |
Actual Study Start Date : | January 6, 2020 |
Estimated Primary Completion Date : | March 31, 2023 |
Estimated Study Completion Date : | March 31, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (pembrolizumab, gemcitabine hydrochloride)
INDUCTION: Patients receive pembrolizumab IV over 25-40 minutes on day 1 of cycles 1-4. Patients also receive gemcitabine hydrochloride intravesically on days 1, 8 and 15 of cycles 1 and 2. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Beginning cycle 5, patients with no evidence of disease after induction receive pembrolizumab IV over 25-40 minutes and gemcitabine intravesically on day 1. Treatment repeats every 3 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity. |
Drug: Gemcitabine Hydrochloride
Given intravesically
Other Names:
Biological: Pembrolizumab Given IV
Other Names:
|
- Complete response rate in the carcinoma in situ (CIS) subpopulation [ Time Frame: At 6 months (end of cycle 8, week 25) ]A complete response, only for patients with a CIS component, is a cystoscopy without evidence of bladder tumor, negative biopsy (including directed biopsies to any suspicious areas and in addition random bladder biopsies including trigone, left lateral wall, right lateral wall, posterior bladder, dome of bladder, and the prostatic urethra in men) and negative cytology for high grade disease.
- Event-free survival at 18 months [ Time Frame: From the date of study registration to the first documentation of an event or death whichever comes first, assessed up to 18 months ]For patients without a documented event and who are still alive, they will be censored at last disease assessment. For patients who start any subsequent ant-cancer therapy without any reported events will be censored at their last disease assessment. will be obtained with a Kaplan-Meier estimator (using the Greenwood formula to estimate the variance) for the entire 153 patient group consisting of patients with CIS, CIS with Ta/T1 or Ta or T1 disease. A 90% confidence interval will be generated for the 18-month EFS estimate.
- Incidence of adverse events [ Time Frame: Up to 5 years post treatment ]Adverse events will be assessed based on the National Cancer Institute (NCI) common toxicity criteria (Common Terminology Criteria for Adverse Events [CTACAE] version [v] 5.0).
- Duration of response (DOR) [ Time Frame: From the time a patient had a documented response that had been confirmed (the time would start at the time a response was first noted) until disease-progression, assessed up to 5 years ]Analysis will only include those patients with a confirmed response. Patients who are alive and without a documented progression at the time of analysis will be censored at the time of the last disease status evaluation. The Kaplan-Meier product-limit estimator will be used to estimate DOR, medians and 95% confidence intervals (CI).
- Progression-free survival (PFS) [ Time Frame: From the date of study registration to the date of progression or death due to any cause, whichever occurs first, assessed up to 5 years ]Surviving patients without any documented progressions will be censored at the date of last known contact. Progression will be defined as the development of muscle invasive bladder cancer or metastatic urothelial cancer (nodal and/or distant). The Kaplan-Meier product-limit estimator will be used to estimate PFS, medians and 95% CI.
- Overall survival (OS) [ Time Frame: From the date of study registration to date of death due to any cause, assessed up to 5 years ]Surviving patients will be censored at the date of last known contact. The Kaplan-Meier product-limit estimator will be used to estimate OS, medians and 95% CI.
- Cystectomy-free survival [ Time Frame: From the date of study registration to the date of cystectomy for all patients ]The Kaplan-Meier product-limit estimator will be used to estimate cystectomy-free survival, medians and 95% CI.
- Recurrence free survival (RFS) [ Time Frame: From the date of study registration to the first documentation of recurrence or death due to any cause, assessed up to 5 years ]Surviving patients without any documented recurrence will be censored at the date of last known contact. Recurrence will be defined as the development of high-grade bladder cancer for patients with a CIS component only and those without a CIS component. The Kaplan-Meier product-limit estimator will be used to estimate RFS, medians and 95% CI.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- High grade Ta, T1 or CIS urothelial carcinoma. Accrual of patients with Ta or T1 disease may be closed to ensure adequate patients enrollment to meet the primary endpoint
-
Persistent disease after completing therapy with at least induction BCG (>= 5 doses) and the first round of maintenance or second induction course (>= 2 doses)
- Persistent high risk NMIBC (T1, high grade Ta and/or CIS) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above
-
High grade T1 after completing therapy with at least induction BCG (>= 5 doses) or after completing therapy with at least induction BCG (>=5 doses) and first round of maintenance or second induction course (>= 2 doses)
- Persistent high risk NMIBC (T1, high grade Ta and/or CIS) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above
- Mixed variant histology (adenocarcinoma, squamous cell carcinoma) is eligible, but pure variant histology is ineligible
-
Patients who are disease free at 6 months after starting BCG but have high grade recurrence (T1, Ta, CIS) while on maintenance therapy would be eligible
- The recurrence must be within 6 months of the last BCG dose
- Patients must be deemed unfit for radical cystectomy by the treating physician or refuse radical cystectomy
-
All visible tumor must be completely resected 60 days prior to registration (residual pure CIS is permitted)
- All patients must have histologically confirmed urothelial cancer of the bladder within 60 days prior to registration. All patients must have had a cystoscopy without papillary tumor and negative urinary cytology within 21 days of registration. (positive cytology is allowed in patients with pure CIS)
- All patients with T1 tumors must undergo a re-staging transurethral resection of bladder tumor (TURBT) within 60 days of registration. There must be uninvolved muscularis propria present in the re-staging TURBT. The initial TURBT prior to re-staging TURBT may be greater than 60 days prior to registration
- Patients must have had imaging with computed tomography (CT) or magnetic resonance imaging (MRI) abdomen/pelvis within 90 days of registration demonstrating no evidence of metastasis.
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects
- Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Include as applicable: Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)
- A WOCBP must not have a positive urine pregnancy test within 7 days prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- Patients must not be pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with registration through the last dose of treatment
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 9.0 g/dL
-
Creatinine =< 1.5 x upper limit of normal (ULN)
- In patients with creatinine > 1.5 x ULN, if measured or calculated creatinine clearance > 30 mL/min, then patient is eligible
-
Total bilirubin =< 1.5 x ULN
- In patients with a total bilirubin > 1.5 x ULN, if direct bilirubin < 1.0 X ULN, then patient is eligible
- Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 2.5 x ULN
-
Patients with human immunodeficiency virus (HIV) are eligible with the following:
- On effective anti-retroviral therapy with undetectable viral load within 6 months of registration
Exclusion Criteria:
- Patients cannot have had a history of urothelial carcinoma in the ureters or prostatic urethra 24 months prior to registration
-
Patients must not be currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to study registration
- Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been more than 4 weeks after the last dose of the previous investigational agent at time of registration
- Patients must not have prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)
- Patients must not have undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years prior to registration. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of graft versus host disease [GVHD])
-
Patients must not have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment
- Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to =< grade 1 or baseline. Participants with =< grade 2 neuropathy may be eligible
- Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
- Patients must not have received prior radiotherapy within 2 weeks of study registration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
- Patients must not have received radiation therapy to the lung that is > 30 Gy within 6 months prior to trial registration
- Patients must not have had an active autoimmune disease requiring systemic treatment within 7 days prior to registration. Autoimmune diseases include, but not limited to, lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis
-
Patients must not have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to registration
- Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- Patients must not have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
- Patients must not have active tuberculosis
- Patients must not have been treated with antibiotics for an active infection within 14 days prior to registration. Prophylactic antibiotics are permitted
- Patients must not have a history of idiopathic pulmonary fibrosis or organizing pneumonia
- Patients must not have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis
- HIV-infected participants must not have a history of Kaposi sarcoma and/or multicentric Castleman disease
- Patients must not have a known additional malignancy that has had progression or has required active treatment in the last three years. Exceptions include basal or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with definitive intent is allowed, provided that the prostate-specific antigen (PSA) is undetectable for at least 1 year while off androgen deprivation therapy
- Patients must not have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
- Patients must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
- Patients must not have an active infection requiring systemic therapy
-
Patients must not have a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected) infection
- Note: No testing for hepatitis B and hepatitis C is required unless mandated by a local health authority
- Patients must not have received live vaccines within 30 days of study drug administration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed
-
Physicians should consider whether any of the following may render the patient inappropriate for this protocol:
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04164082


United States, Alaska | |
Anchorage Associates in Radiation Medicine | Recruiting |
Anchorage, Alaska, United States, 98508 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Anchorage Radiation Therapy Center | Recruiting |
Anchorage, Alaska, United States, 99504 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Alaska Breast Care and Surgery LLC | Recruiting |
Anchorage, Alaska, United States, 99508 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Alaska Oncology and Hematology LLC | Recruiting |
Anchorage, Alaska, United States, 99508 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Alaska Women's Cancer Care | Recruiting |
Anchorage, Alaska, United States, 99508 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Anchorage Oncology Centre | Recruiting |
Anchorage, Alaska, United States, 99508 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Katmai Oncology Group | Recruiting |
Anchorage, Alaska, United States, 99508 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Providence Alaska Medical Center | Recruiting |
Anchorage, Alaska, United States, 99508 | |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org | |
Principal Investigator: Alison K. Conlin | |
Fairbanks Memorial Hospital | Recruiting |
Fairbanks, Alaska, United States, 99701 | |
Contact: Site Public Contact 907-458-3043 Veronica.Stevenson@foundationhealth.org | |
Principal Investigator: Nicholas DiBella | |
United States, Arizona | |
Mayo Clinic Hospital in Arizona | Recruiting |
Phoenix, Arizona, United States, 85054 | |
Contact: Site Public Contact 855-776-0015 | |
Principal Investigator: Mark D. Tyson | |
Mayo Clinic in Arizona | Recruiting |
Scottsdale, Arizona, United States, 85259 | |
Contact: Site Public Contact 855-776-0015 | |
Principal Investigator: Mark D. Tyson | |
United States, Arkansas | |
Mercy Hospital Fort Smith | Recruiting |
Fort Smith, Arkansas, United States, 72903 | |
Contact: Site Public Contact 800-378-9373 | |
Principal Investigator: Jay W. Carlson | |
United States, California | |
Providence Saint Joseph Medical Center/Disney Family Cancer Center | Recruiting |
Burbank, California, United States, 91505 | |
Contact: Site Public Contact 818-847-4793 Najee.Boucher@providence.org | |
Principal Investigator: Alison K. Conlin | |
Cedars Sinai Medical Center | Recruiting |
Los Angeles, California, United States, 90048 | |
Contact: Site Public Contact 310-423-8965 | |
Principal Investigator: Charles J. Rosser | |
University of California Davis Comprehensive Cancer Center | Recruiting |
Sacramento, California, United States, 95817 | |
Contact: Site Public Contact 916-734-3089 | |
Principal Investigator: Marc Dall'Era | |
United States, Colorado | |
Rocky Mountain Cancer Centers-Aurora | Recruiting |
Aurora, Colorado, United States, 80012 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
The Medical Center of Aurora | Recruiting |
Aurora, Colorado, United States, 80012 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Boulder Community Hospital | Suspended |
Boulder, Colorado, United States, 80301 | |
Rocky Mountain Cancer Centers-Boulder | Recruiting |
Boulder, Colorado, United States, 80304 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Rocky Mountain Cancer Centers - Centennial | Recruiting |
Centennial, Colorado, United States, 80112 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Cancer Center of Colorado at Sloan's Lake | Suspended |
Denver, Colorado, United States, 80204 | |
National Jewish Health-Main Campus | Recruiting |
Denver, Colorado, United States, 80206 | |
Contact: Site Public Contact 877-225-5654 glicht@co-cancerresearch.org | |
Principal Investigator: Nicholas DiBella | |
The Women's Imaging Center | Recruiting |
Denver, Colorado, United States, 80209 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Colorado Blood Cancer Institute | Recruiting |
Denver, Colorado, United States, 80218 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Presbyterian - Saint Lukes Medical Center - Health One | Recruiting |
Denver, Colorado, United States, 80218 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Rocky Mountain Cancer Centers-Midtown | Recruiting |
Denver, Colorado, United States, 80218 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
SCL Health Saint Joseph Hospital | Suspended |
Denver, Colorado, United States, 80218 | |
Rocky Mountain Cancer Centers-Rose | Recruiting |
Denver, Colorado, United States, 80220 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Rose Medical Center | Suspended |
Denver, Colorado, United States, 80220 | |
Western Surgical Care | Recruiting |
Denver, Colorado, United States, 80220 | |
Contact: Site Public Contact 303-777-2663 | |
Principal Investigator: Nicholas DiBella | |
Mountain Blue Cancer Care Center - Swedish | Recruiting |
Englewood, Colorado, United States, 80113 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Swedish Medical Center | Recruiting |
Englewood, Colorado, United States, 80113 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
National Jewish Health-Western Hematology Oncology | Recruiting |
Golden, Colorado, United States, 80401 | |
Contact: Site Public Contact 303-777-2663 glicht@co-cancerresearch.org | |
Principal Investigator: Nicholas DiBella | |
Saint Mary's Hospital and Regional Medical Center | Suspended |
Grand Junction, Colorado, United States, 81501 | |
North Colorado Medical Center | Recruiting |
Greeley, Colorado, United States, 80631 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Good Samaritan Medical Center | Suspended |
Lafayette, Colorado, United States, 80026 | |
Rocky Mountain Cancer Centers-Littleton | Recruiting |
Littleton, Colorado, United States, 80120 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Rocky Mountain Cancer Centers-Sky Ridge | Recruiting |
Lone Tree, Colorado, United States, 80124 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
Sky Ridge Medical Center | Recruiting |
Lone Tree, Colorado, United States, 80124 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
McKee Medical Center | Recruiting |
Loveland, Colorado, United States, 80539 | |
Contact: Site Public Contact 303-777-2663 info@westernstatesncorp.org | |
Principal Investigator: Nicholas DiBella | |
National Jewish Health-Northern Hematology Oncology | Recruiting |
Thornton, Colorado, United States, 80260 | |
Contact: Site Public Contact 303-777-2663 glicht@co-cancerresearch.org | |
Principal Investigator: Nicholas DiBella | |
SCL Health Lutheran Medical Center | Suspended |
Wheat Ridge, Colorado, United States, 80033 | |
United States, Florida | |
Holy Cross Hospital | Recruiting |
Fort Lauderdale, Florida, United States, 33308 | |
Contact: Site Public Contact 954-267-7750 | |
Principal Investigator: Tareq Al Baghdadi | |
University of Florida Health Science Center - Gainesville | Recruiting |
Gainesville, Florida, United States, 32610 | |
Contact: Site Public Contact 352-273-8010 cancer-center@ufl.edu | |
Principal Investigator: Paul L. Crispen | |
United States, Hawaii | |
Hawaii Cancer Care - Savio | Recruiting |
'Aiea, Hawaii, United States, 96701 | |
Contact: Site Public Contact 808-539-2273 | |
Principal Investigator: Jeffrey L. Berenberg | |
Pali Momi Medical Center | Recruiting |
'Aiea, Hawaii, United States, 96701 | |
Contact: Site Public Contact 808-486-6000 | |
Principal Investigator: Jeffrey L. Berenberg | |
Queen's Cancer Center - Pearlridge | Recruiting |
'Aiea, Hawaii, United States, 96701 | |
Contact: Site Public Contact 808-487-7447 | |
Principal Investigator: Jeffrey L. Berenberg | |
The Cancer Center of Hawaii-Pali Momi | Recruiting |
'Aiea, Hawaii, United States, 96701 | |
Contact: Site Public Contact 808-678-9000 | |
Principal Investigator: Jeffrey L. Berenberg | |
Hawaii Cancer Care Inc - Waterfront Plaza | Recruiting |
Honolulu, Hawaii, United States, 96813 | |
Contact: Site Public Contact 808-524-6115 i.webster@hawaiicancercare.com | |
Principal Investigator: Jeffrey L. Berenberg | |
Island Urology | Recruiting |
Honolulu, Hawaii, United States, 96813 | |
Contact: Site Public Contact 808-536-2306 virginia@cc.hawaii.edu | |
Principal Investigator: Jeffrey L. Berenberg | |
Queen's Cancer Cenrer - POB I | Recruiting |
Honolulu, Hawaii, United States, 96813 | |
Contact: Site Public Contact 808-532-0315 | |
Principal Investigator: Jeffrey L. Berenberg | |
Queen's Medical Center | Recruiting |
Honolulu, Hawaii, United States, 96813 | |
Contact: Site Public Contact 808-545-8548 | |
Principal Investigator: Jeffrey L. Berenberg | |
Straub Clinic and Hospital | Recruiting |
Honolulu, Hawaii, United States, 96813 | |
Contact: Site Public Contact 808-522-4333 | |
Principal Investigator: Jeffrey L. Berenberg | |
University of Hawaii Cancer Center | Recruiting |
Honolulu, Hawaii, United States, 96813 | |
Contact: Site Public Contact 808-586-2979 | |
Principal Investigator: Jeffrey L. Berenberg | |
Hawaii Cancer Care Inc-Liliha | Recruiting |
Honolulu, Hawaii, United States, 96817 | |
Contact: Site Public Contact 808-536-4888 | |
Principal Investigator: Jeffrey L. Berenberg | |
Kuakini Medical Center | Recruiting |
Honolulu, Hawaii, United States, 96817 | |
Contact: Site Public Contact 808-547-9816 | |
Principal Investigator: Jeffrey L. Berenberg | |
Queen's Cancer Center - Kuakini | Recruiting |
Honolulu, Hawaii, United States, 96817 | |
Contact: Site Public Contact 808-531-8521 | |
Principal Investigator: Jeffrey L. Berenberg | |
The Cancer Center of Hawaii-Liliha | Recruiting |
Honolulu, Hawaii, United States, 96817 | |
Contact: Site Public Contact 808-547-6881 | |
Principal Investigator: Jeffrey L. Berenberg | |
Kapiolani Medical Center for Women and Children | Recruiting |
Honolulu, Hawaii, United States, 96826 | |
Contact: Site Public Contact 808-983-6090 | |
Principal Investigator: Jeffrey L. Berenberg | |
Wilcox Memorial Hospital and Kauai Medical Clinic | Recruiting |
Lihue, Hawaii, United States, 96766 | |
Contact: Site Public Contact 808-535-7960 | |
Principal Investigator: Jeffrey L. Berenberg | |
United States, Idaho | |
Saint Alphonsus Cancer Care Center-Boise | Recruiting |
Boise, Idaho, United States, 83706 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Luke's Cancer Institute - Boise | Recruiting |
Boise, Idaho, United States, 83712 | |
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org | |
Principal Investigator: Alison K. Conlin | |
Saint Alphonsus Cancer Care Center-Caldwell | Recruiting |
Caldwell, Idaho, United States, 83605 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: John M. Schallenkamp | |
Kootenai Medical Center | Recruiting |
Coeur d'Alene, Idaho, United States, 83814 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Walter Knox Memorial Hospital | Recruiting |
Emmett, Idaho, United States, 83617 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Luke's Cancer Institute - Fruitland | Recruiting |
Fruitland, Idaho, United States, 83619 | |
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org | |
Principal Investigator: Alison K. Conlin | |
Idaho Urologic Institute-Meridian | Recruiting |
Meridian, Idaho, United States, 83642 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Luke's Cancer Institute - Meridian | Recruiting |
Meridian, Idaho, United States, 83642 | |
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org | |
Principal Investigator: Alison K. Conlin | |
Saint Alphonsus Medical Center-Nampa | Recruiting |
Nampa, Idaho, United States, 83686 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Luke's Cancer Institute - Nampa | Recruiting |
Nampa, Idaho, United States, 83686 | |
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org | |
Principal Investigator: Alison K. Conlin | |
Kootenai Cancer Center | Recruiting |
Post Falls, Idaho, United States, 83854 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Kootenai Cancer Clinic | Recruiting |
Sandpoint, Idaho, United States, 83864 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Luke's Cancer Institute - Twin Falls | Recruiting |
Twin Falls, Idaho, United States, 83301 | |
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org | |
Principal Investigator: Alison K. Conlin | |
United States, Illinois | |
Illinois CancerCare-Bloomington | Recruiting |
Bloomington, Illinois, United States, 61704 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Canton | Recruiting |
Canton, Illinois, United States, 61520 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Memorial Hospital of Carbondale | Recruiting |
Carbondale, Illinois, United States, 62902 | |
Contact: Site Public Contact 618-457-5200 clinical.research@sih.net | |
Principal Investigator: Bryan A. Faller | |
SIH Cancer Institute | Recruiting |
Carterville, Illinois, United States, 62918 | |
Contact: Site Public Contact 618-985-3333 clinical.research@sih.net | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Carthage | Recruiting |
Carthage, Illinois, United States, 62321 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Centralia Oncology Clinic | Recruiting |
Centralia, Illinois, United States, 62801 | |
Contact: Site Public Contact 217-876-4740 rhamrick@dmhhs.org | |
Principal Investigator: Bryan A. Faller | |
Rush University Medical Center | Recruiting |
Chicago, Illinois, United States, 60612 | |
Contact: Site Public Contact 312-942-5498 clinical_trials@rush.edu | |
Principal Investigator: Srinivas Vourganti | |
Cancer Care Specialists of Illinois - Decatur | Recruiting |
Decatur, Illinois, United States, 62526 | |
Contact: Site Public Contact 217-876-4740 rhamrick@dmhhs.org | |
Principal Investigator: Bryan A. Faller | |
Decatur Memorial Hospital | Recruiting |
Decatur, Illinois, United States, 62526 | |
Contact: Site Public Contact 217-876-4740 rhamrick@dmhhs.org | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Dixon | Recruiting |
Dixon, Illinois, United States, 61021 | |
Contact: Site Public Contact 815-285-7800 | |
Principal Investigator: Bryan A. Faller | |
Crossroads Cancer Center | Recruiting |
Effingham, Illinois, United States, 62401 | |
Contact: Site Public Contact 217-876-4740 rhamrick@dmhhs.org | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Eureka | Recruiting |
Eureka, Illinois, United States, 61530 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Galesburg | Recruiting |
Galesburg, Illinois, United States, 61401 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Western Illinois Cancer Treatment Center | Recruiting |
Galesburg, Illinois, United States, 61401 | |
Contact: Site Public Contact 309-344-2831 | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Kewanee Clinic | Recruiting |
Kewanee, Illinois, United States, 61443 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Macomb | Recruiting |
Macomb, Illinois, United States, 61455 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Loyola University Medical Center | Recruiting |
Maywood, Illinois, United States, 60153 | |
Contact: Site Public Contact 708-226-4357 | |
Principal Investigator: Michael E. Woods | |
Marjorie Weinberg Cancer Center at Loyola-Gottlieb | Recruiting |
Melrose Park, Illinois, United States, 60160 | |
Contact: Site Public Contact 708-450-4554 | |
Principal Investigator: Michael E. Woods | |
Good Samaritan Regional Health Center | Recruiting |
Mount Vernon, Illinois, United States, 62864 | |
Contact: Site Public Contact 618-242-4600 | |
Principal Investigator: Jay W. Carlson | |
Cancer Care Center of O'Fallon | Recruiting |
O'Fallon, Illinois, United States, 62269 | |
Contact: Site Public Contact 217-876-4762 morganthaler.jodi@mhsil.com | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Ottawa Clinic | Recruiting |
Ottawa, Illinois, United States, 61350 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Pekin | Recruiting |
Pekin, Illinois, United States, 61554 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Peoria | Recruiting |
Peoria, Illinois, United States, 61615 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Methodist Medical Center of Illinois | Recruiting |
Peoria, Illinois, United States, 61636 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Peru | Recruiting |
Peru, Illinois, United States, 61354 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Valley Radiation Oncology | Recruiting |
Peru, Illinois, United States, 61354 | |
Contact: Site Public Contact 815-664-4141 | |
Principal Investigator: Bryan A. Faller | |
Illinois CancerCare-Princeton | Recruiting |
Princeton, Illinois, United States, 61356 | |
Contact: Site Public Contact 309-243-3605 andersonj@illinoiscancercare.com | |
Principal Investigator: Bryan A. Faller | |
Southern Illinois University School of Medicine | Recruiting |
Springfield, Illinois, United States, 62702 | |
Contact: Site Public Contact 217-545-7929 | |
Principal Investigator: Bryan A. Faller | |
Springfield Clinic | Recruiting |
Springfield, Illinois, United States, 62702 | |
Contact: Site Public Contact 800-444-7541 | |
Principal Investigator: Bryan A. Faller | |
Memorial Medical Center | Recruiting |
Springfield, Illinois, United States, 62781 | |
Contact: Site Public Contact 217-788-3528 | |
Principal Investigator: Bryan A. Faller | |
Southwest Illinois Health Services LLP | Suspended |
Swansea, Illinois, United States, 62226 | |
United States, Indiana | |
Reid Health | Recruiting |
Richmond, Indiana, United States, 47374 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Memorial Hospital of South Bend | Suspended |
South Bend, Indiana, United States, 46601 | |
United States, Kentucky | |
University of Kentucky/Markey Cancer Center | Recruiting |
Lexington, Kentucky, United States, 40536 | |
Contact: Site Public Contact 859-257-3379 | |
Principal Investigator: Peng Wang | |
United States, Louisiana | |
East Jefferson General Hospital | Recruiting |
Metairie, Louisiana, United States, 70006 | |
Contact: Site Public Contact 504-210-3539 emede1@lsuhsc.edu | |
Principal Investigator: Scott E. Delacroix | |
LSU Healthcare Network / Metairie Multi-Specialty Clinic | Recruiting |
Metairie, Louisiana, United States, 70006 | |
Contact: Site Public Contact 504-210-3539 emede1@lsuhsc.edu | |
Principal Investigator: Scott E. Delacroix | |
Louisiana State University Health Science Center | Recruiting |
New Orleans, Louisiana, United States, 70112 | |
Contact: Site Public Contact 504-210-3539 emede1@lsuhsc.edu | |
Principal Investigator: Scott E. Delacroix | |
United States, Maryland | |
UM Baltimore Washington Medical Center/Tate Cancer Center | Recruiting |
Glen Burnie, Maryland, United States, 21061 | |
Contact: Site Public Contact 410-553-8100 | |
Principal Investigator: Cherif N. Boutros | |
United States, Massachusetts | |
Mercy Medical Center | Suspended |
Springfield, Massachusetts, United States, 01104 | |
United States, Michigan | |
Hickman Cancer Center | Recruiting |
Adrian, Michigan, United States, 49221 | |
Contact: Site Public Contact 517-265-0116 | |
Principal Investigator: Rex B. Mowat | |
Saint Joseph Mercy Hospital | Recruiting |
Ann Arbor, Michigan, United States, 48106 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Bronson Battle Creek | Recruiting |
Battle Creek, Michigan, United States, 49017 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
IHA Hematology Oncology Consultants-Brighton | Recruiting |
Brighton, Michigan, United States, 48114 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint Joseph Mercy Brighton | Recruiting |
Brighton, Michigan, United States, 48114 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
IHA Hematology Oncology Consultants-Canton | Recruiting |
Canton, Michigan, United States, 48188 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint Joseph Mercy Canton | Recruiting |
Canton, Michigan, United States, 48188 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Caro Cancer Center | Recruiting |
Caro, Michigan, United States, 48723 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
IHA Hematology Oncology Consultants-Chelsea | Recruiting |
Chelsea, Michigan, United States, 48118 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint Joseph Mercy Chelsea | Recruiting |
Chelsea, Michigan, United States, 48118 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Hematology Oncology Consultants-Clarkston | Recruiting |
Clarkston, Michigan, United States, 48346 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Newland Medical Associates-Clarkston | Recruiting |
Clarkston, Michigan, United States, 48346 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Ascension Saint John Hospital | Recruiting |
Detroit, Michigan, United States, 48236 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Great Lakes Cancer Management Specialists-Doctors Park | Recruiting |
East China Township, Michigan, United States, 48054 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Genesee Cancer and Blood Disease Treatment Center | Recruiting |
Flint, Michigan, United States, 48503 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Genesee Hematology Oncology PC | Recruiting |
Flint, Michigan, United States, 48503 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Genesys Hurley Cancer Institute | Recruiting |
Flint, Michigan, United States, 48503 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Hurley Medical Center | Recruiting |
Flint, Michigan, United States, 48503 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Helen DeVos Children's Hospital at Spectrum Health | Recruiting |
Grand Rapids, Michigan, United States, 49503 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Mercy Health Saint Mary's | Recruiting |
Grand Rapids, Michigan, United States, 49503 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Spectrum Health at Butterworth Campus | Recruiting |
Grand Rapids, Michigan, United States, 49503 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Academic Hematology Oncology Specialists | Recruiting |
Grosse Pointe Woods, Michigan, United States, 48236 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center | Recruiting |
Grosse Pointe Woods, Michigan, United States, 48236 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Michigan Breast Specialists-Grosse Pointe Woods | Recruiting |
Grosse Pointe Woods, Michigan, United States, 48236 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Bronson Methodist Hospital | Recruiting |
Kalamazoo, Michigan, United States, 49007 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
West Michigan Cancer Center | Recruiting |
Kalamazoo, Michigan, United States, 49007 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Borgess Medical Center | Recruiting |
Kalamazoo, Michigan, United States, 49048 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Sparrow Hospital | Recruiting |
Lansing, Michigan, United States, 48912 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Hope Cancer Clinic | Recruiting |
Livonia, Michigan, United States, 48154 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint Mary Mercy Hospital | Recruiting |
Livonia, Michigan, United States, 48154 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Great Lakes Cancer Management Specialists-Macomb Medical Campus | Recruiting |
Macomb, Michigan, United States, 48044 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Michigan Breast Specialists-Macomb Township | Recruiting |
Macomb, Michigan, United States, 48044 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint Mary's Oncology/Hematology Associates of Marlette | Recruiting |
Marlette, Michigan, United States, 48453 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Toledo Clinic Cancer Centers-Monroe | Recruiting |
Monroe, Michigan, United States, 48162 | |
Contact: Site Public Contact 800-444-3561 | |
Principal Investigator: Rex B. Mowat | |
Mercy Health Mercy Campus | Recruiting |
Muskegon, Michigan, United States, 49444 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Lakeland Hospital Niles | Recruiting |
Niles, Michigan, United States, 49120 | |
Contact: Site Public Contact 616-391-1230 | |
Principal Investigator: Kathleen J. Yost | |
Cancer and Hematology Centers of Western Michigan - Norton Shores | Recruiting |
Norton Shores, Michigan, United States, 49444 | |
Contact: Site Public Contact 616-391-1230 connie.szczepanek@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
21st Century Oncology-Pontiac | Recruiting |
Pontiac, Michigan, United States, 48341 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Hope Cancer Center | Recruiting |
Pontiac, Michigan, United States, 48341 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Newland Medical Associates-Pontiac | Recruiting |
Pontiac, Michigan, United States, 48341 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint Joseph Mercy Oakland | Recruiting |
Pontiac, Michigan, United States, 48341 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Spectrum Health Reed City Hospital | Recruiting |
Reed City, Michigan, United States, 49677 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Great Lakes Cancer Management Specialists-Rochester Hills | Suspended |
Rochester Hills, Michigan, United States, 48309 | |
Ascension Saint Mary's Hospital | Recruiting |
Saginaw, Michigan, United States, 48601 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Oncology Hematology Associates of Saginaw Valley PC | Recruiting |
Saginaw, Michigan, United States, 48604 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Lakeland Medical Center Saint Joseph | Recruiting |
Saint Joseph, Michigan, United States, 49085 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Marie Yeager Cancer Center | Recruiting |
Saint Joseph, Michigan, United States, 49085 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Bhadresh Nayak MD PC-Sterling Heights | Recruiting |
Sterling Heights, Michigan, United States, 48312 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Ascension Saint Joseph Hospital | Recruiting |
Tawas City, Michigan, United States, 48764 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Munson Medical Center | Recruiting |
Traverse City, Michigan, United States, 49684 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Advanced Breast Care Center PLLC | Recruiting |
Warren, Michigan, United States, 48088 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Great Lakes Cancer Management Specialists-Macomb Professional Building | Recruiting |
Warren, Michigan, United States, 48093 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Macomb Hematology Oncology PC | Recruiting |
Warren, Michigan, United States, 48093 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Michigan Breast Specialists-Warren | Recruiting |
Warren, Michigan, United States, 48093 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint John Macomb-Oakland Hospital | Recruiting |
Warren, Michigan, United States, 48093 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Saint Mary's Oncology/Hematology Associates of West Branch | Recruiting |
West Branch, Michigan, United States, 48661 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Metro Health Hospital | Recruiting |
Wyoming, Michigan, United States, 49519 | |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org | |
Principal Investigator: Kathleen J. Yost | |
Huron Gastroenterology PC | Recruiting |
Ypsilanti, Michigan, United States, 48106 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
IHA Hematology Oncology Consultants-Ann Arbor | Recruiting |
Ypsilanti, Michigan, United States, 48197 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
United States, Minnesota | |
Fairview Ridges Hospital | Recruiting |
Burnsville, Minnesota, United States, 55337 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Minnesota Oncology - Burnsville | Recruiting |
Burnsville, Minnesota, United States, 55337 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Cambridge Medical Center | Recruiting |
Cambridge, Minnesota, United States, 55008 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Mercy Hospital | Recruiting |
Coon Rapids, Minnesota, United States, 55433 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Fairview Southdale Hospital | Recruiting |
Edina, Minnesota, United States, 55435 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Unity Hospital | Recruiting |
Fridley, Minnesota, United States, 55432 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Fairview Clinics and Surgery Center Maple Grove | Recruiting |
Maple Grove, Minnesota, United States, 55369 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Minnesota Oncology Hematology PA-Maplewood | Recruiting |
Maplewood, Minnesota, United States, 55109 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Saint John's Hospital - Healtheast | Recruiting |
Maplewood, Minnesota, United States, 55109 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Abbott-Northwestern Hospital | Recruiting |
Minneapolis, Minnesota, United States, 55407 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Hennepin County Medical Center | Recruiting |
Minneapolis, Minnesota, United States, 55415 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Health Partners Inc | Recruiting |
Minneapolis, Minnesota, United States, 55454 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Monticello Cancer Center | Recruiting |
Monticello, Minnesota, United States, 55362 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
New Ulm Medical Center | Recruiting |
New Ulm, Minnesota, United States, 56073 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Fairview Northland Medical Center | Recruiting |
Princeton, Minnesota, United States, 55371 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
North Memorial Medical Health Center | Recruiting |
Robbinsdale, Minnesota, United States, 55422 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Park Nicollet Clinic - Saint Louis Park | Recruiting |
Saint Louis Park, Minnesota, United States, 55416 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Regions Hospital | Recruiting |
Saint Paul, Minnesota, United States, 55101 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
United Hospital | Recruiting |
Saint Paul, Minnesota, United States, 55102 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Saint Francis Regional Medical Center | Recruiting |
Shakopee, Minnesota, United States, 55379 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Lakeview Hospital | Recruiting |
Stillwater, Minnesota, United States, 55082 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Ridgeview Medical Center | Recruiting |
Waconia, Minnesota, United States, 55387 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Rice Memorial Hospital | Recruiting |
Willmar, Minnesota, United States, 56201 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Minnesota Oncology Hematology PA-Woodbury | Recruiting |
Woodbury, Minnesota, United States, 55125 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
Fairview Lakes Medical Center | Recruiting |
Wyoming, Minnesota, United States, 55092 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
United States, Missouri | |
Saint Louis Cancer and Breast Institute-Ballwin | Recruiting |
Ballwin, Missouri, United States, 63011 | |
Contact: Site Public Contact 314-251-7058 | |
Principal Investigator: Jay W. Carlson | |
Cox Cancer Center Branson | Suspended |
Branson, Missouri, United States, 65616 | |
Saint Francis Medical Center | Recruiting |
Cape Girardeau, Missouri, United States, 63703 | |
Contact: Site Public Contact 573-334-2230 sfmc@sfmc.net | |
Principal Investigator: Bryan A. Faller | |
Southeast Cancer Center | Recruiting |
Cape Girardeau, Missouri, United States, 63703 | |
Contact: Site Public Contact 573-651-5550 | |
Principal Investigator: Bryan A. Faller | |
University of Missouri - Ellis Fischel | Recruiting |
Columbia, Missouri, United States, 65212 | |
Contact: Site Public Contact 573-882-7440 | |
Principal Investigator: Katie S. Murray | |
Parkland Health Center - Farmington | Recruiting |
Farmington, Missouri, United States, 63640 | |
Contact: Site Public Contact 314-996-5569 | |
Principal Investigator: Bryan A. Faller | |
Capital Region Southwest Campus | Recruiting |
Jefferson City, Missouri, United States, 65109 | |
Contact: Site Public Contact 573-632-4814 swooden@mail.crmc.org | |
Principal Investigator: Bryan A. Faller | |
Freeman Health System | Recruiting |
Joplin, Missouri, United States, 64804 | |
Contact: Site Public Contact 417-347-4030 LJCrockett@freemanhealth.com | |
Principal Investigator: Jay W. Carlson | |
Mercy Hospital Joplin | Recruiting |
Joplin, Missouri, United States, 64804 | |
Contact: Site Public Contact 417-556-3074 esmeralda.carrillo@mercy.net | |
Principal Investigator: Jay W. Carlson | |
Delbert Day Cancer Institute at PCRMC | Recruiting |
Rolla, Missouri, United States, 65401 | |
Contact: Site Public Contact 573-458-8776 kaysmith@phelpshealth.org | |
Principal Investigator: Jay W. Carlson | |
Mercy Clinic-Rolla-Cancer and Hematology | Recruiting |
Rolla, Missouri, United States, 65401 | |
Contact: Site Public Contact 573-458-6379 | |
Principal Investigator: Jay W. Carlson | |
Heartland Regional Medical Center | Recruiting |
Saint Joseph, Missouri, United States, 64506 | |
Contact: Site Public Contact 816-271-7937 linda.schumacher@mymlc.com | |
Principal Investigator: Jay W. Carlson | |
Saint Louis Cancer and Breast Institute-South City | Recruiting |
Saint Louis, Missouri, United States, 63109 | |
Contact: Site Public Contact 314-353-1870 | |
Principal Investigator: Jay W. Carlson | |
Mercy Hospital South | Recruiting |
Saint Louis, Missouri, United States, 63128 | |
Contact: Site Public Contact janet.lesko@mercy.net | |
Principal Investigator: Jay W. Carlson | |
Missouri Baptist Medical Center | Recruiting |
Saint Louis, Missouri, United States, 63131 | |
Contact: Site Public Contact 314-996-5569 | |
Principal Investigator: Bryan A. Faller | |
Mercy Hospital Saint Louis | Recruiting |
Saint Louis, Missouri, United States, 63141 | |
Contact: Site Public Contact 314-251-7066 | |
Principal Investigator: Jay W. Carlson | |
Sainte Genevieve County Memorial Hospital | Recruiting |
Sainte Genevieve, Missouri, United States, 63670 | |
Contact: Site Public Contact 314-996-5569 | |
Principal Investigator: Bryan A. Faller | |
Mercy Hospital Springfield | Recruiting |
Springfield, Missouri, United States, 65804 | |
Contact: Site Public Contact 417-269-4520 | |
Principal Investigator: Jay W. Carlson | |
CoxHealth South Hospital | Recruiting |
Springfield, Missouri, United States, 65807 | |
Contact: Site Public Contact 417-269-4520 | |
Principal Investigator: Jay W. Carlson | |
Missouri Baptist Sullivan Hospital | Recruiting |
Sullivan, Missouri, United States, 63080 | |
Contact: Site Public Contact 314-996-5569 | |
Principal Investigator: Bryan A. Faller | |
Missouri Baptist Outpatient Center-Sunset Hills | Recruiting |
Sunset Hills, Missouri, United States, 63127 | |
Contact: Site Public Contact 314-996-5569 | |
Principal Investigator: Bryan A. Faller | |
Mercy Hospital Washington | Recruiting |
Washington, Missouri, United States, 63090 | |
Contact: Site Public Contact 636-390-1600 | |
Principal Investigator: Jay W. Carlson | |
United States, Montana | |
Community Hospital of Anaconda | Recruiting |
Anaconda, Montana, United States, 59711 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Billings Clinic Cancer Center | Recruiting |
Billings, Montana, United States, 59101 | |
Contact: Site Public Contact 800-996-2663 research@billingsclinic.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Vincent Healthcare | Suspended |
Billings, Montana, United States, 59101 | |
Saint Vincent Frontier Cancer Center | Suspended |
Billings, Montana, United States, 59102 | |
Bozeman Deaconess Hospital | Recruiting |
Bozeman, Montana, United States, 59715 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Saint James Community Hospital and Cancer Treatment Center | Suspended |
Butte, Montana, United States, 59701 | |
Benefis Healthcare- Sletten Cancer Institute | Recruiting |
Great Falls, Montana, United States, 59405 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Great Falls Clinic | Recruiting |
Great Falls, Montana, United States, 59405 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Kalispell Regional Medical Center | Recruiting |
Kalispell, Montana, United States, 59901 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Patrick Hospital - Community Hospital | Recruiting |
Missoula, Montana, United States, 59802 | |
Contact: Site Public Contact 406-327-3118 amy.hanneman@providence.org | |
Principal Investigator: Alison K. Conlin | |
Community Medical Hospital | Recruiting |
Missoula, Montana, United States, 59804 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
United States, New Hampshire | |
Dartmouth Hitchcock Medical Center | Recruiting |
Lebanon, New Hampshire, United States, 03756 | |
Contact: Site Public Contact 800-639-6918 cancer.research.nurse@dartmouth.edu | |
Principal Investigator: Einar F. Sverrisson | |
United States, New Jersey | |
Memorial Sloan Kettering Basking Ridge | Recruiting |
Basking Ridge, New Jersey, United States, 07920 | |
Contact: Site Public Contact 212-639-7592 | |
Principal Investigator: Eugene J. Pietzak | |
Memorial Sloan Kettering Monmouth | Recruiting |
Middletown, New Jersey, United States, 07748 | |
Contact: Site Public Contact 212-639-7592 | |
Principal Investigator: Eugene J. Pietzak | |
Memorial Sloan Kettering Bergen | Recruiting |
Montvale, New Jersey, United States, 07645 | |
Contact: Site Public Contact 212-639-7592 | |
Principal Investigator: Eugene J. Pietzak | |
The Valley Hospital-Luckow Pavilion | Recruiting |
Paramus, New Jersey, United States, 07652 | |
Contact: Site Public Contact 201-634-5792 | |
Principal Investigator: Eli D. Kirshner | |
Neurosurgeons of New Jersey-Ridgewood | Recruiting |
Ridgewood, New Jersey, United States, 07450 | |
Contact: Site Public Contact 773-702-9171 protocols@AllianceNCTN.org | |
Principal Investigator: Eli D. Kirshner | |
Valley Hospital | Recruiting |
Ridgewood, New Jersey, United States, 07450 | |
Contact: Site Public Contact 201-634-5792 cparish@valleyhealth.com | |
Principal Investigator: Eli D. Kirshner | |
Valley Health System-Hematology/Oncology | Recruiting |
Westwood, New Jersey, United States, 07675 | |
Contact: Site Public Contact 773-702-9171 protocols@AllianceNCTN.org | |
Principal Investigator: Eli D. Kirshner | |
United States, New York | |
Memorial Sloan Kettering Commack | Recruiting |
Commack, New York, United States, 11725 | |
Contact: Site Public Contact 212-639-7592 | |
Principal Investigator: Eugene J. Pietzak | |
The New York Hospital Medical Center of Queens | Recruiting |
Flushing, New York, United States, 11355 | |
Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com | |
Principal Investigator: David A. Green | |
Memorial Sloan Kettering Westchester | Recruiting |
Harrison, New York, United States, 10604 | |
Contact: Site Public Contact 212-639-7592 | |
Principal Investigator: Eugene J. Pietzak | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Site Public Contact 212-639-7592 | |
Principal Investigator: Eugene J. Pietzak | |
NYP/Weill Cornell Medical Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Site Public Contact 212-746-1848 | |
Principal Investigator: Cora N. Sternberg | |
Memorial Sloan Kettering Nassau | Recruiting |
Uniondale, New York, United States, 11553 | |
Contact: Site Public Contact 212-639-7592 | |
Principal Investigator: Eugene J. Pietzak | |
United States, North Carolina | |
UNC Lineberger Comprehensive Cancer Center | Recruiting |
Chapel Hill, North Carolina, United States, 27599 | |
Contact: Site Public Contact 877-668-0683 cancerclinicaltrials@med.unc.edu | |
Principal Investigator: Matthew I. Milowsky | |
University of North Carolina-Hillsborough Campus | Recruiting |
Hillsborough, North Carolina, United States, 27278 | |
Contact: Site Public Contact 877-668-0683 cancerclinicaltrials@med.unc.edu | |
Principal Investigator: Matthew I. Milowsky | |
United States, Ohio | |
Indu and Raj Soin Medical Center | Recruiting |
Beavercreek, Ohio, United States, 45431 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Saint Elizabeth Boardman Hospital | Recruiting |
Boardman, Ohio, United States, 44512 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Dayton Physicians LLC-Miami Valley South | Recruiting |
Centerville, Ohio, United States, 45459 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Miami Valley Hospital South | Recruiting |
Centerville, Ohio, United States, 45459 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Oncology Hematology Care Inc-Kenwood | Recruiting |
Cincinnati, Ohio, United States, 45236 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Miami Valley Hospital | Recruiting |
Dayton, Ohio, United States, 45409 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Dayton Physician LLC-Miami Valley Hospital North | Recruiting |
Dayton, Ohio, United States, 45415 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Miami Valley Hospital North | Recruiting |
Dayton, Ohio, United States, 45415 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Armes Family Cancer Center | Recruiting |
Findlay, Ohio, United States, 45840 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Blanchard Valley Hospital | Recruiting |
Findlay, Ohio, United States, 45840 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Orion Cancer Care | Recruiting |
Findlay, Ohio, United States, 45840 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Atrium Medical Center-Middletown Regional Hospital | Recruiting |
Franklin, Ohio, United States, 45005-1066 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Dayton Physicians LLC-Atrium | Recruiting |
Franklin, Ohio, United States, 45005 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Dayton Physicians LLC-Wayne | Recruiting |
Greenville, Ohio, United States, 45331 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Wayne Hospital | Recruiting |
Greenville, Ohio, United States, 45331 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Greater Dayton Cancer Center | Recruiting |
Kettering, Ohio, United States, 45409 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
First Dayton Cancer Care | Suspended |
Kettering, Ohio, United States, 45420 | |
Kettering Medical Center | Recruiting |
Kettering, Ohio, United States, 45429 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Mercy Health Perrysburg Cancer Center | Suspended |
Perrysburg, Ohio, United States, 43551 | |
Springfield Regional Cancer Center | Suspended |
Springfield, Ohio, United States, 45504 | |
Springfield Regional Medical Center | Suspended |
Springfield, Ohio, United States, 45505 | |
Mercy Health - Saint Anne Hospital | Recruiting |
Toledo, Ohio, United States, 43623 | |
Contact: Site Public Contact 614-488-2118 sheree@columbusccop.org | |
Principal Investigator: Rex B. Mowat | |
Toledo Clinic Cancer Centers-Toledo | Recruiting |
Toledo, Ohio, United States, 43623 | |
Contact: Site Public Contact 800-444-3561 | |
Principal Investigator: Rex B. Mowat | |
Dayton Physicians LLC-Upper Valley | Recruiting |
Troy, Ohio, United States, 45373 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Upper Valley Medical Center | Recruiting |
Troy, Ohio, United States, 45373 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Saint Joseph Warren Hospital | Recruiting |
Warren, Ohio, United States, 44484 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
Saint Elizabeth Youngstown Hospital | Recruiting |
Youngstown, Ohio, United States, 44501 | |
Contact: Site Public Contact 937-528-2900 clinical.trials@daytonncorp.org | |
Principal Investigator: Howard M. Gross | |
United States, Oklahoma | |
University of Oklahoma Health Sciences Center | Recruiting |
Oklahoma City, Oklahoma, United States, 73104 | |
Contact: Site Public Contact 405-271-8777 ou-clinical-trials@ouhsc.edu | |
Principal Investigator: Sanjay G. Patel | |
Mercy Hospital Oklahoma City | Recruiting |
Oklahoma City, Oklahoma, United States, 73120 | |
Contact: Site Public Contact 405-752-3402 | |
Principal Investigator: Jay W. Carlson | |
United States, Oregon | |
Saint Alphonsus Medical Center-Baker City | Recruiting |
Baker City, Oregon, United States, 97814 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: John M. Schallenkamp | |
Saint Charles Health System | Recruiting |
Bend, Oregon, United States, 97701 | |
Contact: Site Public Contact 541-706-2909 nosall@stcharleshealthcare.org | |
Principal Investigator: Alison K. Conlin | |
Clackamas Radiation Oncology Center | Recruiting |
Clackamas, Oregon, United States, 97015 | |
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org | |
Principal Investigator: Alison K. Conlin | |
Providence Cancer Institute Clackamas Clinic | Recruiting |
Clackamas, Oregon, United States, 97015 | |
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org | |
Principal Investigator: Alison K. Conlin | |
Bay Area Hospital | Recruiting |
Coos Bay, Oregon, United States, 97420 | |
Contact: Site Public Contact 541-269-8392 cherie.cox@bayareahospital.org | |
Principal Investigator: Alison K. Conlin | |
Providence Newberg Medical Center | Recruiting |
Newberg, Oregon, United States, 97132 | |
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org | |
Principal Investigator: Alison K. Conlin | |
Saint Alphonsus Medical Center-Ontario | Recruiting |
Ontario, Oregon, United States, 97914 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: John M. Schallenkamp | |
Providence Portland Medical Center | Recruiting |
Portland, Oregon, United States, 97213 | |
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org | |
Principal Investigator: Alison K. Conlin | |
Providence Saint Vincent Medical Center | Recruiting |
Portland, Oregon, United States, 97225 | |
Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org | |
Principal Investigator: Alison K. Conlin | |
Saint Charles Health System-Redmond | Recruiting |
Redmond, Oregon, United States, 97756 | |
Contact: Site Public Contact 541-706-2909 | |
Principal Investigator: Alison K. Conlin | |
United States, Pennsylvania | |
Lehigh Valley Hospital-Cedar Crest | Recruiting |
Allentown, Pennsylvania, United States, 18103 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Lehigh Valley Hospital - Muhlenberg | Recruiting |
Bethlehem, Pennsylvania, United States, 18017 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Pocono Medical Center | Recruiting |
East Stroudsburg, Pennsylvania, United States, 18301 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
Lehigh Valley Hospital-Hazleton | Recruiting |
Hazleton, Pennsylvania, United States, 18201 | |
Contact: Site Public Contact 734-712-3671 stephanie.couch@stjoeshealth.org | |
Principal Investigator: Tareq Al Baghdadi | |
United States, South Carolina | |
Ralph H Johnson VA Medical Center | Recruiting |
Charleston, South Carolina, United States, 29401 | |
Contact: Site Public Contact 843-789-7020 ashley.salvo@va.gov | |
Principal Investigator: Stephen J. Savage | |
United States, Texas | |
University of Texas Medical Branch | Active, not recruiting |
Galveston, Texas, United States, 77555-0565 | |
UTMB Cancer Center at Victory Lakes | Active, not recruiting |
League City, Texas, United States, 77573 | |
Audie L Murphy VA Hospital | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Site Public Contact 877-469-5300 | |
Principal Investigator: Paromita Datta | |
University of Texas Health Science Center at San Antonio | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Site Public Contact 210-450-3800 phoresearchoffice@uthscsa.edu | |
Principal Investigator: Chethan Ramamurthy | |
United States, Utah | |
American Fork Hospital / Huntsman Intermountain Cancer Center | Suspended |
American Fork, Utah, United States, 84003 | |
Sandra L Maxwell Cancer Center | Suspended |
Cedar City, Utah, United States, 84720 | |
Logan Regional Hospital | Suspended |
Logan, Utah, United States, 84321 | |
Intermountain Medical Center | Suspended |
Murray, Utah, United States, 84107 | |
McKay-Dee Hospital Center | Suspended |
Ogden, Utah, United States, 84403 | |
Utah Valley Regional Medical Center | Suspended |
Provo, Utah, United States, 84604 | |
Riverton Hospital | Suspended |
Riverton, Utah, United States, 84065 | |
Dixie Medical Center Regional Cancer Center | Suspended |
Saint George, Utah, United States, 84770 | |
Utah Cancer Specialists-Salt Lake City | Suspended |
Salt Lake City, Utah, United States, 84106 | |
LDS Hospital | Suspended |
Salt Lake City, Utah, United States, 84143 | |
United States, Washington | |
Providence Regional Cancer System-Aberdeen | Recruiting |
Aberdeen, Washington, United States, 98520 | |
Contact: Site Public Contact 360-412-8958 deidre.dillon@providence.org | |
Principal Investigator: Alison K. Conlin | |
MultiCare Auburn Medical Center | Suspended |
Auburn, Washington, United States, 98001 | |
PeaceHealth Saint Joseph Medical Center | Recruiting |
Bellingham, Washington, United States, 98225 | |
Contact: Site Public Contact 360-788-8238 lkey@peacehealth.org | |
Principal Investigator: Alison K. Conlin | |
Providence Regional Cancer System-Centralia | Recruiting |
Centralia, Washington, United States, 98531 | |
Contact: Site Public Contact 360-412-8958 deidre.dillon@providence.org | |
Principal Investigator: Alison K. Conlin | |
Swedish Cancer Institute-Edmonds | Recruiting |
Edmonds, Washington, United States, 98026 | |
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org | |
Principal Investigator: Alison K. Conlin | |
Providence Regional Cancer Partnership | Recruiting |
Everett, Washington, United States, 98201 | |
Contact: Site Public Contact 425-261-3529 marilyn.birchman@providence.org | |
Principal Investigator: Alison K. Conlin | |
MultiCare Gig Harbor Medical Park | Suspended |
Gig Harbor, Washington, United States, 98335 | |
Swedish Cancer Institute-Issaquah | Recruiting |
Issaquah, Washington, United States, 98029 | |
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org | |
Principal Investigator: Alison K. Conlin | |
Kadlec Clinic Hematology and Oncology | Recruiting |
Kennewick, Washington, United States, 99336 | |
Contact: Site Public Contact 509-783-4637 research@kadlecmed.org | |
Principal Investigator: Alison K. Conlin | |
Providence Regional Cancer System-Lacey | Recruiting |
Lacey, Washington, United States, 98503 | |
Contact: Site Public Contact 360-412-8958 deidre.dillon@providence.org | |
Principal Investigator: Alison K. Conlin | |
PeaceHealth Saint John Medical Center | Recruiting |
Longview, Washington, United States, 98632 | |
Contact: Site Public Contact 360-514-2016 kmakin-bond@peacehealth.org | |
Principal Investigator: Alison K. Conlin | |
Jefferson Healthcare | Recruiting |
Port Townsend, Washington, United States, 98368 | |
Contact: Site Public Contact 360-344-3091 | |
Principal Investigator: Nicholas DiBella | |
MultiCare Good Samaritan Hospital | Suspended |
Puyallup, Washington, United States, 98372 | |
Pacific Gynecology Specialists | Recruiting |
Seattle, Washington, United States, 98104 | |
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org | |
Principal Investigator: Alison K. Conlin | |
Swedish Medical Center-Ballard Campus | Recruiting |
Seattle, Washington, United States, 98107 | |
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org | |
Principal Investigator: Alison K. Conlin | |
Swedish Medical Center-First Hill | Recruiting |
Seattle, Washington, United States, 98122-4307 | |
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org | |
Principal Investigator: Alison K. Conlin | |
Swedish Medical Center-Cherry Hill | Recruiting |
Seattle, Washington, United States, 98122-5711 | |
Contact: Site Public Contact 206-215-3086 PCRC-NCORP@Swedish.org | |
Principal Investigator: Alison K. Conlin | |
PeaceHealth United General Medical Center | Recruiting |
Sedro-Woolley, Washington, United States, 98284 | |
Contact: Site Public Contact 360-788-8238 lkey@peacehealth.org | |
Principal Investigator: Alison K. Conlin | |
Providence Regional Cancer System-Shelton | Recruiting |
Shelton, Washington, United States, 98584 | |
Contact: Site Public Contact 360-412-8958 deidre.dillon@providence.org | |
Principal Investigator: Alison K. Conlin | |
MultiCare Deaconess Cancer and Blood Specialty Center - Valley | Suspended |
Spokane Valley, Washington, United States, 99216 | |
MultiCare Deaconess Cancer and Blood Specialty Center - Downtown | Suspended |
Spokane, Washington, United States, 99204 | |
MultiCare Deaconess Cancer and Blood Specialty Center - North | Suspended |
Spokane, Washington, United States, 99218 | |
MultiCare Tacoma General Hospital | Suspended |
Tacoma, Washington, United States, 98405 | |
PeaceHealth Southwest Medical Center | Recruiting |
Vancouver, Washington, United States, 98664 | |
Contact: Site Public Contact 360-514-3940 kmakin-bond@peacehealth.org | |
Principal Investigator: Alison K. Conlin | |
Providence Saint Mary Regional Cancer Center | Recruiting |
Walla Walla, Washington, United States, 99362 | |
Contact: Site Public Contact 509-897-5993 Cheryl.Dodd@providence.org | |
Principal Investigator: Alison K. Conlin | |
Providence Regional Cancer System-Yelm | Recruiting |
Yelm, Washington, United States, 98597 | |
Contact: Site Public Contact 360-412-8958 deidre.dillon@providence.org | |
Principal Investigator: Alison K. Conlin | |
United States, Wisconsin | |
Marshfield Medical Center-EC Cancer Center | Recruiting |
Eau Claire, Wisconsin, United States, 54701 | |
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org | |
Principal Investigator: Michael Husak | |
Marshfield Medical Center-Marshfield | Recruiting |
Marshfield, Wisconsin, United States, 54449 | |
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org | |
Principal Investigator: Michael Husak | |
Medical College of Wisconsin | Recruiting |
Milwaukee, Wisconsin, United States, 53226 | |
Contact: Site Public Contact 414-805-3666 | |
Principal Investigator: Scott Johnson | |
Marshfield Clinic-Minocqua Center | Recruiting |
Minocqua, Wisconsin, United States, 54548 | |
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org | |
Principal Investigator: Michael Husak | |
ProHealth D N Greenwald Center | Recruiting |
Mukwonago, Wisconsin, United States, 53149 | |
Contact: Site Public Contact research.institute@phci.org | |
Principal Investigator: Timothy R. Wassenaar | |
Cancer Center of Western Wisconsin | Recruiting |
New Richmond, Wisconsin, United States, 54017 | |
Contact: Site Public Contact 952-993-1517 mmcorc@healthpartners.com | |
Principal Investigator: Daniel M. Anderson | |
ProHealth Oconomowoc Memorial Hospital | Recruiting |
Oconomowoc, Wisconsin, United States, 53066 | |
Contact: Site Public Contact 262-928-7878 | |
Principal Investigator: Timothy R. Wassenaar | |
Marshfield Medical Center-Rice Lake | Recruiting |
Rice Lake, Wisconsin, United States, 54868 | |
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org | |
Principal Investigator: Michael Husak | |
Marshfield Clinic Stevens Point Center | Recruiting |
Stevens Point, Wisconsin, United States, 54482 | |
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org | |
Principal Investigator: Michael Husak | |
ProHealth Waukesha Memorial Hospital | Recruiting |
Waukesha, Wisconsin, United States, 53188 | |
Contact: Site Public Contact 262-928-7632 | |
Principal Investigator: Timothy R. Wassenaar | |
UW Cancer Center at ProHealth Care | Recruiting |
Waukesha, Wisconsin, United States, 53188 | |
Contact: Site Public Contact 262-928-5539 Chanda.miller@phci.org | |
Principal Investigator: Timothy R. Wassenaar | |
Marshfield Medical Center - Weston | Recruiting |
Weston, Wisconsin, United States, 54476 | |
Contact: Site Public Contact 800-782-8581 oncology.clinical.trials@marshfieldresearch.org | |
Principal Investigator: Michael Husak | |
United States, Wyoming | |
Cheyenne Regional Medical Center-West | Recruiting |
Cheyenne, Wyoming, United States, 82001 | |
Contact: Site Public Contact 303-777-2663 ccrp@co-cancerresearch.org | |
Principal Investigator: Nicholas DiBella | |
Billings Clinic-Cody | Recruiting |
Cody, Wyoming, United States, 82414 | |
Contact: Site Public Contact 800-996-2663 research@billingsclinic.org | |
Principal Investigator: John M. Schallenkamp | |
Welch Cancer Center | Recruiting |
Sheridan, Wyoming, United States, 82801 | |
Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org | |
Principal Investigator: John M. Schallenkamp | |
Guam | |
FHP Health Center-Guam | Recruiting |
Tamuning, Guam, 96913 | |
Contact: Site Public Contact 671-646-5825 | |
Principal Investigator: Jeffrey L. Berenberg | |
Puerto Rico | |
Cancer Center-Metro Medical Center Bayamon | Recruiting |
Bayamon, Puerto Rico, 00959-5060 | |
Contact: Site Public Contact 787-395-7085 | |
Principal Investigator: Luis Baez-Diaz | |
HIMA San Pablo Oncologic Hospital | Recruiting |
Caguas, Puerto Rico, 00726 | |
Contact: Site Public Contact 787-653-3434 | |
Principal Investigator: Luis Baez-Diaz | |
Doctors Cancer Center | Recruiting |
Manati, Puerto Rico, 00674 | |
Contact: Site Public Contact 787-621-4397 | |
Principal Investigator: Luis Baez-Diaz | |
Instituto Oncologia Moderna Ponce | Recruiting |
Ponce, Puerto Rico, 00716 | |
Contact: Site Public Contact 787-848-0606 | |
Principal Investigator: Luis Baez-Diaz | |
San Juan Community Oncology Group | Recruiting |
San Juan, Puerto Rico, 00917 | |
Contact: Site Public Contact 787-274-3387 | |
Principal Investigator: Luis Baez-Diaz | |
Centro Comprensivo de Cancer de UPR | Recruiting |
San Juan, Puerto Rico, 00927 | |
Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com | |
Principal Investigator: Luis Baez-Diaz | |
San Juan City Hospital | Recruiting |
San Juan, Puerto Rico, 00936 | |
Contact: Site Public Contact 787-763-1296 | |
Principal Investigator: Luis Baez-Diaz |
Principal Investigator: | Michael E Woods | Alliance for Clinical Trials in Oncology |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT04164082 |
Other Study ID Numbers: |
NCI-2019-07573 NCI-2019-07573 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) A031803 ( Other Identifier: Alliance for Clinical Trials in Oncology ) A031803 ( Other Identifier: CTEP ) U10CA180821 ( U.S. NIH Grant/Contract ) |
First Posted: | November 15, 2019 Key Record Dates |
Last Update Posted: | February 24, 2021 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page. |
URL: | https://grants.nih.gov/policy/sharing.htm |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Urinary Bladder Neoplasms Carcinoma in Situ Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Urinary Bladder Diseases Urologic Diseases Gemcitabine |
Pembrolizumab Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Immunological |